Table 3

Change in PSA outcome variables needed for assessing cDAPSA and MDA

VariableUST
Baseline
TNFi
Baseline
UST
Change at 6 months
TNFi
Change at 6 months
cDAPSA31.0 (28.9 to 33.1)29.8 (27.9 to 31.7)−13.7 (−15.5 to −11.8)−14.6 (−16.2 to −13.0)
Tender joint count—68 joints12.5 (11.2 to 13.7)11.3 (10.3 to 12.4)−5.3 (−6.4 to −4.2)−5.7 (−6.6 to −4.8)
Swollen joint count—66 joints6.0 (5.2 to 6.8)5.8 (5.1 to 6.5)−3.7 (−4.4 to −3.0)−3.7 (−4.4 to −3.1)
HAQ-DI assessment1.1 (1.1 to 1.2)1.2 (1.1 to 1.2)−0.25 (−0.3 to −0.2)−0.34 (−0.4 to −0.3)
Physician Global Assessment of Disease—VAS, mm53.5 (51.6 to 55.3)54.7 (52.7 to 56.6)−23.3 (−25.7 to −20.8)−24.9 (−27.3 to −22.6)
Patient Global Assessment of Disease— VAS, mm61.1 (58.8 to 63.5)61.1 (58.7 to 63.4)−20.7 (−23.5 to −18.0)−25.2 (−28.2 to −22.3)
Patient assessment of pain—VAS*, mm60.6 (58.1 to 63.0)61.2 (58.9 to 63.5)−19.1 (−21.9 to −16.2)−24.4 (−27.2 to −21.6)
Total enthesitis score (LEI)2.6 (2.4 to 2.8)2.6 (2.4 to 2.8)−1.4 (−1.6 to −1.2)−1.5 (−1.7 to −1.2)
Psoriasis BSA distribution, n (%) (95% CI)
 Clear/almost clear skin99 (28.8) (24.1 to 33.9)123 (34.1) (29.2 to 39.2)312 (59.1) (54.8 to 63.3)335 (63.6) (59.3 to 67.7)
 <3% but not clear/almost clear33 (9.6) (6.7 to 13.2)58 (16.1) (12.4 to 20.3)70 (13.3) (10.5 to 16.5)85 (16.1) (13.1 to 19.6)
 3%‒10%120 (34.9) (29.9 to 40.2)129 (35.7) (30.8 to 40.9)133 (25.2) (21.5 to 29.1)93 (17.6) (14.5 to 21.2)
 >10%92 (26.7) (22.1 to 31.8)51 (14.1) (10.7 to 18.2)13 (2.5) (1.3 to 4.2)14 (2.7) (1.5 to 4.4)
Psoriasis BSA improvement† from baseline, n (%)184 (53.5) (48.1 to 58.9)166 (46.0) (40.8 to 51.3)
  • Data are observed mean (95% CI) at month 6 (last observation carried forward), unless otherwise indicated.

  • *There was a significantly higher percentage of UST patients with chronic widespread pain (FiRST score).

  • †Improvement: at least one category.

  • BSA, body surface area; cDAPSA, clinical Disease Activity Index for Psoriatic Arthritis; HAQ-DI, Health Assessment Questionnaire Disability Index; LEI, Leeds Enthesitis Index; MDA, minimal disease activity; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor; UST, ustekinumab; VAS, visual analogue scale.